Prospective Study of DCEP Chemotherapy in Patients with Relapsed or Refractory Multiple Myeloma

Journal Title: Scholars Journal of Applied Medical Sciences - Year 2018, Vol 6, Issue 12

Abstract

Abstract: Multiple myeloma (MM) is the 2nd most common haematological malignancy among the elderly. Majority of MM patients develop refractoriness/relapse to conventional agents and in such patients, chemotherapy is one of the treatment options. However, prospective data on DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin) chemotherapy is limited. This phase II prospective study intends to find out the response rate, toxicity and survival outcomes of DCEP infusional chemotherapy in relapsed or refractory MM patients (RRMM) who failed ≥ 2 conventional lines of treatment (including bortezomib and one of the IMiDs). The study period was from January 2012 to December 2013. Twenty one patients were recruited into the study. The median age was 48 years (range 38-63y). Male:female ratio was 12:9. ISS stage I, II and III were equally distributed. Of the 21 patients, 15 completed 6 cycles of DCEP chemotherapy, 4 discontinued and 2 expired after 1st cycle (cause being pneumonia and dengue haemorrhagic fever). Eight (53.3%) had an overall response (complete, very good partial and partial response). The 2 yr and 5 yr progression free survival (PFS) was 10.5% and 5.3% respectively. The 2 yr and 5 yr overall survival (OS) was 46.4% and 37.2% respectively. At a median follow up of 29.1 months, the median PFS was 9.3 months [95% CI 5.2-13.4m] and the median OS was 21.4 months [95% CI 0-46.0m]. There were 5 grade 3/4 haematological toxicities which was managed with prophylactic growth factors and appropriate supportive care. At 5 yr follow up, 4 patients are alive, of whom 3 are on subsequent novel agents and one continues to be in remission. DCEP chemotherapy has good response rate with manageable toxicity and should be considered as a salvage option in RRMM patients. Molecular studies in RRMM are needed to find patients who may get durable benefit with infusional chemotherapy regimens.

Authors and Affiliations

Lakshmi Haridas K, Geetha Narayanan, Sreejith G Nair

Keywords

Related Articles

Compare stress intensity of root canal therapy specialists, dentistry residents and students during root canal therapy stages in Hamadan School of Dentistry in 2014-15

Abstract: The main objective of the present study is to compare the stress intensity during root canal therapy stages among root canal therapy specialists, residents and students.The study population consists of all dent...

Assessment of the Level of Homocysteine in Acute Coronary Syndrome Patients Vis-A-Vis Chronic Stable Angina Patients

Abstract: Coronary Artery Disease is a major cause of morbidity and mortality in the modern society. The major classic cardiovascular risk factors and such non-modifiable risk factors such as age, sex, and family history...

Role of Brain-Derived Neurotrophic Factor on Cognition of Hypothyroid Neonatal Rats

Mechanisms underlying the effects of inadequate thyroid hormone availability to the brain, on cognitive functions are not completely understood. The aim of this study is to assess if dysregulation of Brain derived neurot...

Comparison of Polyglactin 910 Rapide versus Chromic catgut for episiotomy repair

With the objective of comparing the efficacy of polyglactin 910 rapide in continuous locking technique versus chromic catgut in interrupted technique for episiotomy repair regarding perineal pain, analgesic requirement,...

Evaluation of various tests of amsels criteria for diagnosis of bacterial vaginosis in patients of preterm labor

Bacterial vaginosis is the most common vaginal infection in women of reproductive age.. We undertook this study to evaluate various tests of amsels criteria for diagnosis of bacterial vaginosis in preterm patients consid...

Download PDF file
  • EP ID EP480137
  • DOI -
  • Views 44
  • Downloads 0

How To Cite

Lakshmi Haridas K, Geetha Narayanan, Sreejith G Nair (2018). Prospective Study of DCEP Chemotherapy in Patients with Relapsed or Refractory Multiple Myeloma. Scholars Journal of Applied Medical Sciences, 6(12), 4704-4709. https://europub.co.uk/articles/-A-480137